265 filings
Page 3 of 14
8-K
0gpawkyvxjm
11 Feb 19
Immunomedics Announces Oral Presentation at the 2019 Genitourinary Cancers Symposium
5:25pm
8-K
7n99qg8jxd7r54a
7 Feb 19
Other Events
4:30pm
8-K
olk77cxbf2v5o45zj79k
18 Jan 19
Immunomedics Receives Complete Response Letter from Fda for Sacituzumab Govitecan Biologics License Application
12:00am
8-K
79fgeef6 pqb4scep4jc
16 Jan 19
Other Events
12:00am
8-K
h9z xebmthzbfb1h93
28 Dec 18
Entry into a Material Definitive Agreement
8:58am
8-K
dnambey 9jk7
26 Dec 18
Immunomedics and Johnson Matthey Announce Strategic Manufacturing Partnership
8:30am
8-K
hqzwic7zqt2ynh97w
17 Dec 18
Amendments to Articles of Incorporation or Bylaws
5:01pm
8-K
xfl3wk
7 Nov 18
Immunomedics Announces First Quarter Fiscal 2019 Results and Provides Corporate Update
4:06pm
8-K
o2wiac3w 9i7qo
3 Oct 18
Entry into a Material Definitive Agreement
8:15am
8-K
qa69g7gxss0xsyq
28 Sep 18
Departure of Directors or Certain Officers
4:30pm
8-K
2ofmuoxpx03al00o4
12 Sep 18
Immunomedics and Samsung Biologics Announce Strategic Manufacturing Partnership
12:00am
8-K
04xu 4p9w9z
23 Aug 18
Departure of Directors or Certain Officers
12:00am
8-K
jpy 8asdi7
23 Aug 18
Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update
12:00am
8-K
kwybe4882xrmmshq
18 Jul 18
Other Events
8:15am
8-K
tt8w80ks5tk6a fcxd
12 Jul 18
Entry into a Material Definitive Agreement
4:30pm
8-K
ndvx1 n3mdbka8ojdla
22 Jun 18
Other Events
4:33pm
8-K
4e7ibzctt1
15 Jun 18
Immunomedics Announces Proposed Public Offering of Common Stock
4:00pm
8-K
zqd 5vdb8ql
4 Jun 18
Immunomedics Announces Pivotal Study of Sacituzumab Govitecan In Patients with Locally Advanced or Metastatic Urothelial Cancer
12:00am
8-K
uemqehj1z2 suboyrrp
4 Jun 18
Immunomedics Provides Business Update at the Asco 2018 Investor Event
12:00am
8-K
5de hxhet7vtr
9 May 18
Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update
4:01pm